AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00432367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine
Description: Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use.
Study NCT01211873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem (gadoterate meglumine)
Description: 0.1 mmol/kg by body weight, single IV injection
Study NCT01211873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist (gadopentetate dimeglumine)
Description: 0.1 mmol/kg by body weight, single IV injection
Study NCT03451474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper extremity nerve transfer surgery
Description: Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
Study NCT04059861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
Study NCT04669756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovariopexy
Description: if endometriosis was removed from the pelvic side wall or the ovary or both leading to an open wound adjacent to the ovary, ovariopexy was performed on both sides using a transabdominal-transovarian suture being tied extracorporeally on the patients Skin leading to uplifting of the ovary to the abdominal wall
Study NCT04669756 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo operation
Description: in arm D sutures are transabdominal only
Study NCT00288106 — intervention group
Intervention type: OTHER
Intervention: Follow-up
Description: No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
Study NCT02046239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture Group
Study NCT02046239 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Staple Group (control)
Study NCT02525627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident cup, X3 inserts, 28 mm head
Description: Orthopaedic implant
Study NCT02525627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident cup, X3 inserts, 40 mm head
Description: Orthopaedic implant
Study NCT02525627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Symax stem
Description: Orthopaedic implant
Study NCT02525627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade TMZF stem
Description: Orthopaedic implant
Study NCT02944097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vineatrol 30 native powder
Study NCT02944097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vineatrol 30 micelles
Study NCT01881178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NOPALEA
Study NCT01881178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NOPALEA
Study NCT03962881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Description: three-dose, 20 µg per dose
Study NCT03962881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6
Description: four-dose, 20 µg per dose
Study NCT03962881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6
Description: four-dose, 60 µg per dose
Study NCT03090399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FloTrac
Description: For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
Study NCT01140815 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Smith and Nephew Total Knee Replacement
Study NCT01140815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deuce
Description: Smith and Nephew Bicompartmental Knee Replacement
Study NCT04698005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25g Ketone monoester without added salts
Description: oral supplementation of ketone monoester
Study NCT04698005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive a placebo drink (drinking water) of equivalent volume (3x 65ml)
Study NCT03350880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
Study NCT03350880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility training
Description: Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
Study NCT03367949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical guide designed from Impression inversion with markers
Description: Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
Study NCT01590537 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
Study NCT01590537 — intervention group
Intervention type: DEVICE
Intervention: Copper IUD
Description: Copper device, inserted intrauterine
Study NCT01833897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
Study NCT01833897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
Study NCT01833897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
Study NCT04365127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 100 MG
Description: Subcutaneous administration twice daily
Study NCT04518475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag combining rituximab
Description: After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.
Study NCT04518475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.
Study NCT03469141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Relief Monitoring System
Description: Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
Study NCT03902249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT03902249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Study NCT02694393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
Study NCT01302639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Description: EGCG, resveratol and genistein
Study NCT03587402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous perineal stimulation
Description: Surface stimulation
Study NCT01302639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Description: EGCG, resveratol and genistein
Study NCT04040738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity surgery under general anaesthesia
Description: Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
Study NCT04040738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity surgery under regional anaesthesia
Description: Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
Study NCT01910701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit
Description: The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
Study NCT04551027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compensatory cognitive treatment
Description: a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
Study NCT01416194 — intervention group
Intervention type: DRUG
Intervention: Bazedoxifene
Description: Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
Study NCT01416194 — intervention group
Intervention type: DRUG
Intervention: Bisphosphonate
Description: Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
Study NCT01416194 — intervention group
Intervention type: DRUG
Intervention: Raloxifene
Description: Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
Study NCT03970434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Venous blood collection
Study NCT03970434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Peripheral blood collection
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic for complicated intra-abdominal infection
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Antibiotic for complicated intra-abdominal infection
Study NCT04692753 — intervention group
Intervention type: OTHER
Intervention: Training and education
Description: Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
Study NCT03537625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
Study NCT03537625 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea
Description: We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
Study NCT02230228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001 (No generic name)
Description: Daily, oral administration of ALK-001 capsules.
Study NCT04082533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Study NCT04082533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water (D5W)
Description: Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic for complicated intra-abdominal infection
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotic for complicated intra-abdominal infection
Study NCT04624256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Patients and physicians engage in discussion
Study NCT04624256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo conventional hypofractionated radiation therapy
Study NCT04624256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo moderate hypofractionated radiation therapy
Study NCT04624256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04624256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04624256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04624256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02414165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
Study NCT02414165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Study NCT02414165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Study NCT02414165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study NCT02414165 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT03284515 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccination with a pertussis containing vaccine
Description: Vaccination with a pertussis containing vaccine
Study NCT00798707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 25 mg tablet, once daily dosing for 8 weeks
Study NCT00798707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 50 mg tablet, once daily dosing for 8 weeks
Study NCT00798707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study NCT01742390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
Study NCT01742390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone or paliperidone
Study NCT02741609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Borrelia Diagnostic Test
Description: The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
Study NCT00537056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET CT
Description: nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
Study NCT00537056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
Study NCT03587402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anal stimulation
Description: Intra-cavitary stimulation
Study NCT01894919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate
Description: Antibiotic for complicated intra-abdominal infection
Study NCT03358576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: Antibiotic for complicated intra-abdominal infection
Study NCT03996928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT03996928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT02053727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
Study NCT02053727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04142541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)
Description: The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
Study NCT03927157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT03927157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Study NCT00537056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoro-deoxi-glucose
Description: 15 mCi iv
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Study NCT02285751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel